Drugs / HIVAC-1e
last change Dec 1994 re-read 2 minutes ago

HIVAC-1e

also known as vaccinia-HIV

Vaccine

Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · Bristol-Myers Squibb

Trials 6 · a red edge is where a trial was stopped

199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00000746 ? → Jul 1994 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00002261 HIV infectious disease Bristol-Myers Squibb Completed No outcome recorded
Phase 1 NCT00000683 ? → Jun 1993 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000631 ? → Dec 1992 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00001026 ? → Dec 1994 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00000630 ? → Dec 1992 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as HIVAC-1e ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000631
5

NCT00000746

NCT00000683

NCT00002261

NCT00001026

NCT00000630

Known as vaccinia-HIV “the HIVAC-1e (vaccinia-HIV) vaccine expressing the envelope glycoproteins of HIV” NCT00002261
Modality Vaccine “two candidate HIV vaccines, HIVAC-1e and gp160” NCT00000630
Route Other “These immunizations are administered by scarification on the arm” NCT00000683